Low-dose azathioprine and allopurinol versus azathioprine monotherapy in patients with ulcerative colitis (AAUC): An investigator-initiated, open, multicenter, parallel-arm, randomised controlled trial

Marianne Kiszka-Kanowitz, Klaus Theede, Sandra Bohn Thomsen, Jacob Tveiten Bjerrum, Jørn Brynskov, Ida Benedikte Gottschalck, Elena Akimenko, Karen Lisa Hilsted, Anders Neumann, Signe Wildt, Lone Larsen, Jens Kristian Munk, Per Holger Ibsen, Huma Gul Rehana Janjua, Lise Lotte Gluud, Anette Mertz-Nielsen, Marianne Kiszka-Kanowitz, Klaus Theede, Sandra Bohn Thomsen, Jacob Tveiten Bjerrum, Jørn Brynskov, Ida Benedikte Gottschalck, Elena Akimenko, Karen Lisa Hilsted, Anders Neumann, Signe Wildt, Lone Larsen, Jens Kristian Munk, Per Holger Ibsen, Huma Gul Rehana Janjua, Lise Lotte Gluud, Anette Mertz-Nielsen

Abstract

Background: Retrospective studies suggest that for patients with ulcerative colitis (UC) combination therapy with low-dose azathioprine and allopurinol (L-AZA/ALLO) may result in higher remission rates than monotherapy with azathioprine (AZA). We prospectively investigated the effects of these drugs for remission in patients with moderate-to-severe UC.

Methods: Open-label, unblinded, randomised, controlled, investigator-initiated, multicentre study conducted at eight hospital sites in Denmark. Adult patients with established UC, who were steroid dependent/refractory, thiopurine naïve, had a normal thiopurine methyltransferase, and achieved remission with steroids or infliximab were eligible for inclusion. Patients were randomly assigned by the investigators (1:1) to 52 weeks of treatment with once daily oral AZA (median dose 50 mg) combined with ALLO 100 mg versus AZA monotherapy (median dose 200 mg), using a computer-generated randomisation list with blocks of six. The trial was open without masking. All randomised patients who received at least one dose of study drug were included in primary and safety analyses (intention to treat population). The primary outcome was steroid and infliximab free remission after 52 weeks, defined as a Mayo Score of ≤1 and no rectal bleeding. The trial is completed and is registered in ClinicalTrials.gov (ClinicalTrials.gov NCT03101800).

Findings: Between January 9, 2017 and February 10, 2021, 47 patients were randomised to l-AZA/ALLO and 42 to AZA and received at least one dose of the study drug. After 52 weeks, 20 of 47 (43%) patients in the l-AZA/ALLO group and nine of 42 (21%) patients in the AZA group achieved remission (odds ratio 2·54 [95% CI 1·00 to 6.78, p < 0·048]). Fourteen patients (30%) in the l-AZA/ALLO group and 16 (38%) in the AZA group were withdrawn from the study due to adverse events.

Interpretation: This study suggests that after one year l-AZA/ALLO therapy may be associated with a beneficial effect on steroid- and infliximab-free clinical remission in patients with moderate-to-severe UC and should be considered as first line therapy.

Funding: Funding for AAUC was provided by The Capital Region of Denmark (Regionernes Medicinpulje (6062/16)).

Keywords: Allopurinol; Azathioprine; Randomised trial; Reatment; Ulcerative colitis.

Conflict of interest statement

MKK, LLG, EA, IBG, LL, JTB, JKM, KLH, AN, PHI, and HGRJ: none. AMN, SBT: Has received a grant from The Regions Medicinepulje to conduct the study. SW: Has received personal fees from Takeda and Tillotts outside the submitted work. JB: Has been a consultant and/or received advisory board fees and/or research grants from Abbvie, MSD, Takeda, Janssen, Pfizer, Bristol Myers Squibb and Gilead. KT: Has received personal fees from Ferring Lægemidler A/S, Takeda, Tillotts and Pfizer outside the submitted work. AN: Has received grants from Pharmacosmos and non-financial support from Janssen and Takeda, outside the submitted work.

© 2022 The Authors.

Figures

Figure 1
Figure 1
Trial profile

References

    1. Rubin D., Ananthakrishnan A.N., Siegel C.A., Sauer B.G., Long M.D. ACG clinical guideline. Ulcerative colitis in adults. Am J Gastroenterol. 2019;114:384–413.
    1. Hanauer S.B., Sandborn W.J., Lichtenstein G.R. Evolving considerations for thiopurine therapy for inflammatory bowel diseases - a clinical practice update: commentary. Gastroenterology. 2019;156:36–42.
    1. Colombel J.F., Sandborn W.J., Reinisch W., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362:1383–1395.
    1. Smith M.A., Blaker P., Marinaki A.M., Anderson S.H., Irving P.M., Sanderson J.D. Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol. J Crohns Colitis. 2012;6:905–912.
    1. Dassopoulos T., Dubinsky M.C., Bentsen J.L., et al. Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease. AP&T. 2014;39:163–175.
    1. Kiszka-Kanowitz M., Theede K., Mertz-Nielsen A. Randomized clinical trial: a pilot study comparing efficacy of low-dose azathioprine and allopurinol to azathioprine on clinical outcomes in inflammatory bowel disease. Scand J Gastroenterol. 2016;51:1470–1475.
    1. Elion G.B. The purine path to chemotherapy. Science. 1989;244:41–47.
    1. Ansari A., Elliott T., Baburajan B., et al. Long term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. AP&T. 2008;28:734–741.
    1. Sparrow M.P., Hande S.A., Friedman S., et al. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. AP&T. 2005;22:441–446.
    1. Sparrow M.P., Hande S.A., Friedman S., Cao D., Hanauer S.B. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol. 2007;5:209–214.
    1. Leung Y., Sparrow M.P., Schwartz M., Hanauer S.B. Long term efficacy and safty of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease. J Crohns Colitis. 2009;3:162–167.
    1. Ansari A., Patel N., Sanderson J., O'Donohue J., Duley J.A., Florin T.H. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease. AP&T. 2010;31:640–647.
    1. Friedman A.B., Brown S.J., Bampton P., et al. Randomised clinical trial: efficacy, safety, and dosage of adjunctive allopurinol in azthioprine/mercaptopurine nonresponders (AAA study) AP&T. 2018;47:1092–1102.
    1. Hoentjen F., Seinen M.L., Hanauer S.B., et al. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:363–369.
    1. Kirchherr H., Shipkova M., von Ahsen N. Improved method for therapeutic drug monitoring of 6-thioguanine nucleotides and 6-methylmercaptopurine in whole-blood by LC/MSMS using isotope-labeled internal standards. Ther Drug Monit. 2013;35:313–321.
    1. Casteele N.V., Herfarth H., Katz J., Falck-Ytter Y., Singh S. American gastroenterological association institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases. Gastroenterology. 2017;153:835–857.
    1. D'Haens G., Sandborn W.J., Feagan B.G., et al. A review of activity indices and efficacy end points for clinical trials of medical theraphy in adults with ulcerative colitis. Gastroenterology. 2007;132:763–786.
    1. Fiel M., Qin L., Suriawinata A., et al. Histological grading of disease activity in chronic IBD: inter- and intra-observer variation among pathologists with different levels of experience. Mod Pathol. 2003;16:118A.
    1. Theede K., Holck S., Ibsen P., Kallemose T., Nordgaard-Lassen I., Nielsen A.M. Level of faecal calprotectin correlates with endoscopic and histologic inflammation and identifies patients with mucosal healing of ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13:1929–1936.
    1. Theede K., Holck S., Ibsen P., Kallemose T., Nordgaard-Lassen I., Nielsen A.M. Faecal calprotectin predicts relapse and histological mucosal healing in ulcerative colitis. Inflam Bowel Dis. 2016;16:1042–1048.
    1. Hjortswang H., Järnerot G., Curman B., et al. The short health scale: a valid measure of subjective health in ulcerative colitis. Scand J Gastroenterol. 2006;41:1196–1203.
    1. Irvine E.J., Zhou Q., Thompson A.K. The short inflammatory bowel disease questionnaire is reliable and responsive to clinically important change in ulcerative colitis. Am J Gastroenterol. 1996;91:1571–1578.
    1. Stournaras E., Qian W., Pappas A., Hong Y.Y., et al. Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn's disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease. Gut. 2021;70:677–686.
    1. Satohiro M., Hirosato M. Real-world long-term remission maintenance for 10 years with thiopurines in ulcerative colitis. Crohns Colitis. 2021;3:1–9.
    1. Kreijne J.E., de Vries A.C., de Veer R.C., et al. Limited added value of laboratory monitoring in thiopurine maintenance monotherapy in inflammatory bowel disease patients. AP&T. 2020;51:1353–1364.
    1. Hindorf U., Johansson M., Eriksson A., Kvifors E., Almer S.H. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease. AP&T. 2009;15:654–6127.
    1. Biemans V.B.C., Savelkoul E., Gabriëls M., et al. A comparative analysis of tioguanine versus low-dose thiopurines combined with allopurinol in inflammatory bowel disease patients. AP&T. 2020;51:1076–86.28.
    1. Pavlidis P., Stamoulos P., Abdulrehman A., et al. Long-term safety and efficacy of low-dose azathioprine and allopurinol co-therapy in inflammatory bowel disease: a large observational study. Inflamm Bowel Dis. 2016;22:1639–1646.
    1. Thomsen S.B., Allin K.H., Burisch J., et al. Outcome of concomitant treatment with thiopurines and allopurinol in patients with inflammatory bowel disease: a nationwide Danish cohort study. United Eur Gastroenterol J. 2020;8:68–76.
    1. van Liege E., Bayoumy A.B., Mulder C.J.J., et al. Azathioprine with Allopurinol is a promising first-line therapy for inflammatory bowel diseases. Dig Dis Sci. 2021 doi: 10.1007/s10620-021-07273-y. Nov 2Online ahead of print.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner